PSNL News and Press, Personalis Inc. From 08/06/20

Personalis (NASDAQ: PSNL ) : Q2 GAAP EPS of -$0.29 beats by $0.05 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the sec...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with P...

Precision medicine is a new approach to disease management and treatment that takes into account the genetic makeup, lifestyle and environment of each individual patient. The healthcare industry is shifting from a one-size-fits-all approach to a focus on precision medicine, which allows physic...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020. In conjunction with the release, the Company will host a conference call and webcast that d...

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted sto...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the appointment of Leslie Grab as VP of Intellectual Property and John Lyle as VP of Assay Research and Development. Dr. Grab joins Personalis from Verily Life Sciences (a Google spin-out), where sh...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced its completion of the 75,000 th whole human genome sequenced under its contract with the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). All genomes were...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held online, June 22-24,...

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020. Personalis will present “Enabling...